<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002251</url>
  </required_header>
  <id_info>
    <org_study_id>059A</org_study_id>
    <secondary_id>ICM 1775</secondary_id>
    <nct_id>NCT00002251</nct_id>
  </id_info>
  <brief_title>A Multiple Dose Crossover Pharmacokinetics Study to Evaluate the Effects of Food on the Absorption of Oral Ganciclovir</brief_title>
  <official_title>A Multiple Dose Crossover Pharmacokinetics Study to Evaluate the Effects of Food on the Absorption of Oral Ganciclovir</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      This study is designed to determine the influence of food on the absorption and relative&#xD;
      bioavailability of oral ganciclovir by comparing the absorption of oral ganciclovir in a fed&#xD;
      and fasting state at steady state plasma levels.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>20</enrollment>
  <condition>Cytomegalovirus Infections</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ganciclovir</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Patients must have the following:&#xD;
&#xD;
          -  Confirmation of HIV infection by HIV antibody testing, p24 antigen, or culture of HIV.&#xD;
&#xD;
          -  Documented confirmation of present or past CMV infection.&#xD;
&#xD;
          -  Must understand the nature of the study, agree to tests required in the protocol, and&#xD;
             must understand and sign an informed Consent form approved by the appropriate&#xD;
             Institutional Review Board and by Syntex.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following conditions or symptoms are excluded:&#xD;
&#xD;
          -  Uncontrolled diarrhea or clinically significant gastrointestinal symptoms including&#xD;
             persistent nausea or abdominal pain.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Antimetabolites. Interferons. Other nucleoside analogs. Zidovudine (AZT). Any&#xD;
             investigational drug.&#xD;
&#xD;
        Patients with the following are excluded:&#xD;
&#xD;
          -  Any concomitant conditions listed in Exclusion Co-Existing Conditions.&#xD;
&#xD;
          -  Karnofsky score &lt; 70.&#xD;
&#xD;
          -  Hypersensitivity to acyclovir.&#xD;
&#xD;
          -  Displaying signs of dementia or decreased mentation which would interfere with the&#xD;
             ability of the subject to follow protocol schedule.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Anti-cytomegalovirus therapy including ganciclovir therapy for treatment of CMV&#xD;
             disease.&#xD;
&#xD;
          -  Excluded within 4 days of study entry:&#xD;
&#xD;
          -  Antimetabolites.&#xD;
&#xD;
          -  Interferons.&#xD;
&#xD;
          -  Other nucleoside analogs.&#xD;
&#xD;
          -  Zidovudine (AZT).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Davies Med Ctr</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown Univ Med Ctr</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Lavelle J, Follansbee S, Trapnell CB, Buhles WC, Griffy KG, Jung D, Dorr A, Connor J. Effect of food on the relative bioavailability of oral ganciclovir. J Clin Pharmacol. 1996 Mar;36(3):238-41. doi: 10.1002/j.1552-4604.1996.tb04193.x.</citation>
    <PMID>8690817</PMID>
  </reference>
  <verification_date>May 1991</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>AIDS-Related Opportunistic Infections</keyword>
  <keyword>Ganciclovir</keyword>
  <keyword>Cytomegalovirus Infections</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>Biological Availability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Cytomegalovirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ganciclovir</mesh_term>
    <mesh_term>Ganciclovir triphosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

